Email this article 
Myeloproliferative neoplasms (MPNs) – Part 2: A nursing guide to managing the symptom burden of MPNs
Abstract
Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone marrow stem cells. The symptom burden experienced by patients with the BCR-ABL1-negative MPNs (also referred to as the classical MPNs, i.e., essential thrombocythemia [ET], polycythemia vera [PV] and myelofibrosis [MF]) can be significant and can negatively impact quality of life (QOL). Since patients with these MPNs can live for several years, thereby requiring long-term treatment and follow-up, nurses play an essential role in communicating with these patients, assessing their symptoms, and educating them on treatments and self-management strategies that can reduce their symptom burden. This article, which is the second of a two-part series, was developed to provide nurses and other healthcare professionals with practical guidance for managing the symptom burden associated with the classical MPNs in order to help enhance their patients’ overall health and QOL.
Full Text:
PDFReferences
BC Cancer Agency. (2005). Nutritional Guidelines for Symptom Management: Early Satiety. Available online at http://www.bccancer.bc.ca/nutrition-site/Documents/Symptom%20management%20guidelines/EarlySatiety.pdf
Centers for Disease Control and Prevention. (2013). Chronic Fatigue Syndrome. Available at: https://www.cdc.gov/cfs/management/treating-symptoms.html
Cervantes, F. (2011). How I treat splenomegaly in myelofibrosis. Blood Cancer Journal, 1(10), e37.
Emanuel, R.M., Dueck, A.C., Geyer, H.L., Kiladjian, J.J., Slot, S., Zweegman, S., te Boekhorst, P.A., … Mesa. R.A. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103.
Geyer, H.L., Dueck, A.C., Scherber, R.M., & Mesa, R.A. (2015). Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators of Inflammation, 2015, 284706.
Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., … Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787–98.
Harrison, C.N., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Knoops, L., Cervantes, F., … Barbui, T. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib versus best available therapy for myelofibrosis. Leukemia, 30, 1701–1707.
Hermouet, S., Bigot-Corbel, E., & Gardie B. (2015). Pathogenesis of myeloproliferative neoplasms: Role and mechanisms of chronic inflammation. Mediators of Inflammation, 2015, 145293.
Howell, D., Keshavarz, H., Broadfield, L., Hack, T., Hamel, M., Harth, T., Jones, J., … Ali, M, on behalf of the Cancer Journey Advisory Group of the Canadian Partnership Against Cancer. (2015). A Pan Canadian Practice Guideline for Screening, Assessment, and Management of Cancer-Related Fatigue in Adults Version 2-2015, Toronto: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, April 2015.
Mesa, R.A., Gotlib, J., Gupta, V., Catalano, J.V., Deininger, M.W., Shields, A.L., Miller, C.B., … Verstovsek, S. (2013). Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 31(10), 1285–1292.
Mesa, R., Miller, C.B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S., Ma, X., … Mascarenhas, J.O. (2016). Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer, 16, 167.
Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., … Tefferi, A. (2007). The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPN patients. Cancer, 109(1), 68–76.
Mesa, R.A., Scherber, R.M., & Geyer, H.L. (2015). Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leukemia & Lymphoma, 56(7), 1989–1999.
Michiels J.J. (2016). Signs and symptoms of myeloproliferative neoplasms (MPN), quality of life, social activity, work participation and the impact of fatigue in Dutch MPN patients: A one-country questionnaire investigation of 497 MPN patients. Journal of Hematology and Thromboembolic Diseases, 4, 241.
Mughal, T.I., Vaddi, K., Sarlis, N.J & Verstovsek, S. (2014). Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine, 7, 89–101.
Neben-Wittich, M.A., Brown, P.D., & Tefferi, A. (2010). Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fractionradiation therapy. American Journal of Hematology, 85(10), 808–810.
Radia, D., & Geyer, H.L. (2015). Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program, 2015, 340–348.
Saini, K.S., Patnaik, M.M., & Tefferi, A. (2010). Polycythemia vera-associated pruritus and its management. European Journal of Clinical Investigation, 40(9), 828–834.
Scherber, R., Dueck, A.C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., … Mesa, R.A. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood, 118(2), 401–408.
Scherber, R.M., Kosiorek, H.E., Senyak, Z., Dueck, A.C., Clark, M.M., Boxer, M.A., Geyer, H.L., … Mesa, R.A. (2016). Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer, 122, 477–85.
Vannucchi, A.M., Kiladjian, J,J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., … Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426–435.
Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., … Kantarjian, H.M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799–807.
Refbacks
- There are currently no refbacks.
